TrialBlood advances2021

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Cécile Tomowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.